The First Approval for Denecimig Came From Riyadh, Not Washington
- The Saudi Food and Drug Authority approved registration of Frehemgo (denecimig) on 14 September 2026 for routine prophylaxis of bleeding episodes in haemophilia A, with or without factor VIII inhibitors. The SFDA states it is the first regulatory authority globally to approve the product.
- Denecimig had been designated under the SFDA’s Breakthrough Medicines Program before approval. It is a bispecific antibody that mimics activated factor VIII by bridging factor IXa and factor X on the surface of activated platelets, promoting thrombin generation. The mechanism works irrespective of whether factor VIII inhibitors are present.
- Dosing is subcutaneous, once weekly, every 2 weeks or once monthly, according to body weight and physician assessment. Approval rested on 4 Phase 3 studies: an adult and adolescent study, a paediatric study, an all-age open-label extension, and an adult and adolescent safety-only study of patients switching from emicizumab.
- The most common adverse reactions were injection-site reactions including erythema and pruritus, pyrexia, headache and upper respiratory tract infections. Increases were also observed in laboratory markers of coagulation activation, specifically prothrombin fragment 1+2 and D-dimer.
CI read
A Gulf regulator reached a novel bispecific before the FDA or the EMA did, which reverses the usual sequence. The more revealing detail sits in the trial list.
- One of the four Phase 3 studies exists to move patients off a competitor. A safety-only switch study from emicizumab is not a regulatory requirement. It is a programme built to answer the question a haematologist asks before changing a stable patient, which tells you the commercial target was the incumbent rather than the untreated.
- Saudi Arabia is positioning as a launch market rather than a follower. The Breakthrough Medicines Program designated denecimig and then delivered a world-first approval in 2026. For a sponsor, a Gulf first approval now buys real-world exposure and a reference decision ahead of the major agencies rather than after them.
- The coagulation markers are the number to track. Rises in prothrombin fragment 1+2 and D-dimer are the expected pharmacodynamic signature of an agent that promotes thrombin generation, and they are also where the thrombotic safety question lives for this mechanism. Watch how later regulators treat them in labelling.
Read the original source (Saudi Food and Drug Authority) →
CompaniesSFDA
GeographySaudi Arabia